Figure 4 | Scientific Reports

Figure 4

From: Effective clearance of rituximab-resistant tumor cells by breaking the mirror-symmetry of immunoglobulin G and simultaneous binding to CD55 and CD20

Figure 4The alternative text for this image may have been generated using AI.

C1q binding, C4d production, and serum complement–mediated tumor cell killing of SBU-CD55 × CD20. (a) Binding of SBU-CD55 × CD20, rituximab, and 4-1H to C1q detected by ELISA. (b) C4d production of SBU-CD55 × CD20. C4d produced in the presence of serum complements was measured using a C4d ELISA kit, and its signals were compared with those of rituximab. (c–f) CDC of SBU-CD55 × CD20, rituximab, 4-1H, and the combination of two IgG antibodies (rituximab and 4-1H) in lymphoma cell lines: Ramos (c), WSU-NHL (d), Ramos-RR (e), and BJAB (f). Standard errors calculated from triplicate samples are represented by error bars. Standard errors calculated from triplicate samples are represented by error bars. A P-value < 0.01 is represented as **, and a P-value > 0.05 is indicated by “n.s.” for not significant.

Back to article page